血浆IIA分泌型磷脂酶A2水平与冠脉支架术后再狭窄关系

目的：测定稳定型冠心病患者支架植入术（percutanous coronary intervention，PCI）前血浆IIA分泌型磷脂酶A2（group IIA secretory phospholipase A2，IIA-sPLA2）的水平，以探讨该酶与冠脉支架术后再狭窄的可能关系。方法：稳定型冠心病行PCI患者63例，非冠心病患者39例，健康正常对照组42例，分别取外周静脉血测定血浆IIA-sPLA2酶浓度。PCI患者6个月后复查造影。结果：PCI患者术前该酶浓度显著高于正常对照组（P〈0．05），支架内再狭窄率34．9％，再狭窄（restenosis，RS）患者支架术前该酶水平与无再狭窄患者该酶水平无统计学差异（P〉0．05）。结论：PCI患者术前血浆IIA-sPLA2酶浓度显著高于正常对照组，但可能与支架术后再狭窄无关。

Relationship Between Plasma IIA Secretory Phospholipase A2 and Restenosis after Percutanous Coronary Intervention in Patients with Coronary Heart Disease

Objective： To study the correlation between IIA-sPLA2 level and restenosis after percutanous coronary intervention （PCI） in Patients with coronary heart disease. Methods： This study enrolled 63 patients with coronary heart disease （CHD） who underwent successful PCI, 39 patients with non-CHD, and 42 healthy subjects were studied as a control group .Levels of IIA-sPLA2 in plasma were measured by an enzymoimmunoassay using a monoclonal antibody. The patients who underwent PCI had repeat angiograplay at six-month follow-up. Results： The level of IIA-sPLA2 in PCI patients was significantly higher than that in healthy subjects （P〈0.05）, but not higher than that in patients with non-CHD （P〉0.05）. Restenosis occurred in 22 patients （34.9 %）. While there were no significantly changes ofthe levels of IIA-sPLA2 between the patients without or with restenosis. Conclusions： The level oflIA-sPLA2 in patients with coronary heart disease had a significant increase compared to the healthy subjects, but such increase may not be associated with in-stent restenosis.